Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications
HSR26-247: Real-World Quality of Life in Patients Treated With Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma: Results of CemiplimAb Survivorship Epidemiology (CASE) Study.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 16, 2026
HSR26-247: Real-World Quality of Life in Patients Treated With Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma: Results of CemiplimAb Survivorship Epidemiology (CASE) Study.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 01, 2026
Head and neck cancer therapeutic vaccines: a review.
Journal: Frontiers in oncology
Published: December 22, 2025
CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma.
Journal: Future oncology (London, England)
Published: January 11, 2025
A Review of Immunotherapy for Head and Neck Cancer.
Journal: Journal of dental research
Published: October 07, 2024
Novel SZT2::MAST2 Fusion Detected in Salivary Duct Carcinoma.
Journal: Case reports in pathology
Published: August 02, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 20, 2024
Hypofractionated versus standard fractionation radiotherapy for merkel cell carcinoma.
Journal: Radiation oncology (London, England)
Published: May 01, 2024
Head and Neck Squamous Cell Carcinoma of Unknown Primary: A Diagnostic Work-Up.
Journal: The oncologist
Published: September 10, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.
Journal: Journal for immunotherapy of cancer
Published: May 02, 2022
Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: February 07, 2022
Last Updated: 09/26/2026